Geode Capital Management LLC Grows Stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Geode Capital Management LLC lifted its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 5.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,296,156 shares of the company’s stock after buying an additional 66,968 shares during the period. Geode Capital Management LLC’s holdings in Tenaya Therapeutics were worth $2,502,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of TNYA. SG Americas Securities LLC purchased a new position in shares of Tenaya Therapeutics in the 3rd quarter worth $49,000. The Manufacturers Life Insurance Company lifted its position in Tenaya Therapeutics by 43.2% during the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after purchasing an additional 7,000 shares in the last quarter. Algert Global LLC purchased a new position in Tenaya Therapeutics during the second quarter valued at $74,000. XTX Topco Ltd lifted its position in Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after purchasing an additional 16,687 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in Tenaya Therapeutics during the third quarter valued at $134,000. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Tenaya Therapeutics Stock Down 2.0 %

NASDAQ:TNYA opened at $1.49 on Wednesday. The business’s 50-day simple moving average is $2.34 and its two-hundred day simple moving average is $2.51. The stock has a market cap of $118.04 million, a PE ratio of -1.03 and a beta of 2.89. Tenaya Therapeutics, Inc. has a 52 week low of $0.99 and a 52 week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.07. Sell-side analysts anticipate that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th. Canaccord Genuity Group reiterated a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Chardan Capital reiterated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th. Finally, Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Tenaya Therapeutics presently has a consensus rating of “Buy” and an average price target of $17.33.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.